Literature DB >> 30017534

The spectrum of 45,X/46,XY mosaicism in Taiwanese children: The experience of a single center.

Yen-Chun Huang1, Cheng-Ting Lee1, Mu-Zon Wu2, Shih-Yao Liu1, Yi-Ching Tung1, Hong-Nerng Ho3, Wen-Yu Tsai4.   

Abstract

BACKGROUND/
PURPOSE: 45,X/46,XY mosaicism is a rare sex chromosome abnormality. Here, we present our experience in the management of 45,X/46,XY Taiwanese children. PATIENTS AND METHODS: We enrolled 19 patients from January 1981 to September 2016. The diagnosis of 45,X/46,XY mosaicism was made by karyotyping peripheral blood lymphocytes. All medical records were thoroughly reviewed.
RESULTS: Of the 19 patients, 16 were reared as females and 3 as males. The age at diagnosis ranged from 1 month to 15 years and 9 months. Atypical genitalia, short stature, and Turner stigmata were common manifestations. No patient exhibited a cardiac malformation but 29% had renal malformations and 12.5% had autoimmune thyroid disease who developed thyroid dysfunction later. Nine girls with short stature received growth hormone therapy and their height standard deviation score rose from -3.4 ± 1.1 to -1.4 ± 0.9 in adulthood (P < 0.01). The gonadal phenotypes included bilateral streak gonads in nine patients, a streak gonad with contralateral gonadal agenesis in one, mixed gonadal dysgenesis in five, bilateral dysgenetic testes in two, and bilateral gonadoblastomas in one.
CONCLUSION: The 45,X/46,XY phenotype varies widely and a high index of suspicion is important to ensure early diagnosis. Cardiac and renal malformations should be screened ultrasonically at diagnosis and thyroid status should be monitored annually. Growth hormone effectively improves adult height in short girls. Prophylactic gonadectomy is indicated for those with intra-abdominal streaks or dysgenetic gonads to prevent the development of a malignancy.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  45,X/46,XY mosaicism; Gonadoblastoma; Growth hormone therapy; Mixed gonadal dysgenesis; Turner syndrome

Mesh:

Substances:

Year:  2018        PMID: 30017534     DOI: 10.1016/j.jfma.2018.07.003

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

Review 1.  Clinical management in mixed gonadal dysgenesis with chromosomal mosaicism: Considerations in newborns and adolescents.

Authors:  Erica M Weidler; Margaret Pearson; Kathleen van Leeuwen; Erin Garvey
Journal:  Semin Pediatr Surg       Date:  2019-09-19       Impact factor: 2.754

2.  Clinical phenotype and management of individuals with mosaic monosomy X with Y chromosome material stratified by genital phenotype.

Authors:  Lindsey Guzewicz; Susan Howell; Canice E Crerand; Hailey Umbaugh; Natalie J Nokoff; Jennifer Barker; Shanlee M Davis
Journal:  Am J Med Genet A       Date:  2021-02-22       Impact factor: 2.802

3.  Growth data and tumour risk of 32 Chinese children and adolescents with 45,X/46,XY mosaicism.

Authors:  Lili Pan; Zhe Su; Jianming Song; Wanhua Xu; Xia Liu; Longjiang Zhang; Shoulin Li
Journal:  BMC Pediatr       Date:  2019-05-06       Impact factor: 2.125

4.  Multidisciplinary Approach to the Child with Sex Chromosomal Mosaicism Including a Y-Containing Cell Line.

Authors:  Bauke Debo; Marlies Van Loocke; Katya De Groote; Els De Leenheer; Martine Cools
Journal:  Int J Environ Res Public Health       Date:  2021-01-21       Impact factor: 3.390

5.  Chance diagnosis of mixed gonadal dysgenesis in an adult case of malignant gonadal germ cell tumor: a case report.

Authors:  Yoshiko Kurose; Tomonori Nagai; Kousuke Shigematsu; Takahiro Uotani; Taichi Akahori; Yasushi Takai; Hiroyuki Seki
Journal:  J Med Case Rep       Date:  2021-03-28

6.  Prevalence of autoimmune thyroid diseases among the Turner Syndrome patients: meta-analysis of cross sectional studies.

Authors:  Sagad Omer Obeid Mohamed; Ibrahim Hassan Eldaw Elkhidir; Abdelhamid Ibrahim Hassan Abuzied; Ahmed Abdulgadir Mohammed Hassan Noureddin; Gehad Abdelmonem Abdalla Ibrahim; Ahmed Abdallah Ali Mahmoud
Journal:  BMC Res Notes       Date:  2018-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.